CA3192684A1 - Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) - Google Patents

Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Info

Publication number
CA3192684A1
CA3192684A1 CA3192684A CA3192684A CA3192684A1 CA 3192684 A1 CA3192684 A1 CA 3192684A1 CA 3192684 A CA3192684 A CA 3192684A CA 3192684 A CA3192684 A CA 3192684A CA 3192684 A1 CA3192684 A1 CA 3192684A1
Authority
CA
Canada
Prior art keywords
cltx
dosing
cca
blood
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3192684A
Other languages
English (en)
French (fr)
Inventor
Simon BRUCE
Jonathan Fox
Ramei SANI-GROSSO
Ali KOMEYLI
Ananth SRIDHAR
Mary Scott ROBERTS
Michael T. Collins
Rachel I. Gafni
Kelly B. L. Roszko
Iris R. Hartley
Karen A. Pozo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Calcilytix Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3192684A1 publication Critical patent/CA3192684A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3192684A 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) Pending CA3192684A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063080165P 2020-09-18 2020-09-18
US63/080,165 2020-09-18
US202163159397P 2021-03-10 2021-03-10
US63/159,397 2021-03-10
PCT/US2021/050677 WO2022060987A1 (en) 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Publications (1)

Publication Number Publication Date
CA3192684A1 true CA3192684A1 (en) 2022-03-24

Family

ID=78087574

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3192684A Pending CA3192684A1 (en) 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Country Status (10)

Country Link
US (1) US20220087961A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213829A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542932A (cg-RX-API-DMAC7.html)
KR (1) KR20230112609A (cg-RX-API-DMAC7.html)
AU (1) AU2021343475A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192684A1 (cg-RX-API-DMAC7.html)
IL (1) IL301409A (cg-RX-API-DMAC7.html)
MX (1) MX2023003129A (cg-RX-API-DMAC7.html)
TW (1) TW202227046A (cg-RX-API-DMAC7.html)
WO (1) WO2022060987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
WO2024220796A1 (en) * 2023-04-21 2024-10-24 Calcilytix Therapeutics, Inc. Treatment of hypoparathyroidism using triphenyl calcilytic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) * 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
CN116648243A (zh) * 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂

Also Published As

Publication number Publication date
EP4213829A1 (en) 2023-07-26
WO2022060987A1 (en) 2022-03-24
IL301409A (en) 2023-05-01
MX2023003129A (es) 2023-08-04
US20220087961A1 (en) 2022-03-24
AU2021343475A1 (en) 2023-06-01
TW202227046A (zh) 2022-07-16
KR20230112609A (ko) 2023-07-27
AU2021343475A9 (en) 2024-05-02
JP2023542932A (ja) 2023-10-12

Similar Documents

Publication Publication Date Title
Haffner et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
KR100445946B1 (ko) 폐고혈압 치료법
US20140194484A1 (en) Method of Treating Cachexia and Sarcopenia
Palmer A physiologic-based approach to the evaluation of a patient with hyperkalemia
US20220323445A1 (en) Reducing immunogenicity to pegloticase
PT2275086E (pt) Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
Bacchetta et al. X-linked hypophosphatemia and burosumab: practical clinical points from the French experience
Magdaleno et al. Adult-onset hypophosphatasia: before and after treatment with asfotase alfa
US20220087961A1 (en) Treatment methods of triphenyl calcilytic compounds
Clayton et al. Phase I randomized placebo-controlled, double-blind study of the safety and tolerability of bremelanotide coadministered with ethanol in healthy male and female participants
O'Loughlin et al. IRON NOF trial: IV iron for anaemic patients with femoral fracture
JP2002518323A (ja) 選択的エストロゲン受容体修飾物質と上皮小体ホルモンとを含む治療用組合わせ物
Pandey et al. Use of 2MD, a novel oral calcitriol analog, in hemodialysis patients with secondary hyperparathyroidism
JP2002518326A (ja) 筋骨格脆性治療のための(選択的)エストロゲンレセプターモジュレーター(serm)及び成長ホルモン分泌促進剤(ghs)の治療用組合せ
CN116916907A (zh) 用于治疗常染色体显性遗传性低钙血症1型(adh1)的三苯基溶钙化合物
US12208092B2 (en) Compositions and methods for administering paltusotine to patients with hepatic impairment
EP1280555B1 (en) Pharmaceutical composition comprising furosemide and conivaptan for the treatment of congestive heart failure
US20240423961A1 (en) 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
US20210085711A1 (en) Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
US20250222003A1 (en) Pharmaceutical composition for treating solid tumors
TW202506101A (zh) 使用三苯基鈣敏感性化合物之副甲狀腺機能低下症治療
Sato et al. Hypomagnesemia Causing Convulsions in a Patient Taking a Proton Pump Inhibitor: A Case Report
WO2026032924A1 (en) Camlipixant in combination with cyp3a4 and/or cyp2c8 inducers for use in the treatment of chronic cough
Matsumoto et al. Hypercalcemia with the Oral Administration of Active Vitamin D3 and Chinese Herbal Medicine
Moretz Drug Class Literature Scan: Iron Replacement, Oral

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250908

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250908

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250909

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250909

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250909

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251110

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251110

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251110

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251113

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260729

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTERNAL INVESTIGATION REQUEST

Effective date: 20260805